PARP Inhibitor Did Not Increase SCLC Response to Immune Checkpoint Blockade
A preexisting CD8+ T-cell response may be predictive of benefit from checkpoint blockade in SCLC.
Lung Cancer
AI Model Uses Serial Imaging to Predict Lung Cancer Tx Response
For patients with locally advanced non-small cell lung cancer (NSCLC), deep-learning networks integrating computed tomography (CT) scans at multiple time points can improve clinical outcome predictions.
In-House or Centralized Testing? Debating Whether Genomic Sequencing Is Best Conducted at Home
Genomic analysis of tumors and tests measuring certain biomarkers can be done in-house or sent out. What are the costs and benefits of each approach?
What Do Surrogate End Points Actually Predict?
As understanding of cancer improves, drug development could become accelerated, necessitating a means for determining whether a drug is actually effective.
Use of Inhaled Corticosteroids Reduces Lung Cancer Risk in COPD
Sustained use of inhaled corticosteroids is associated with a reduced risk for lung cancer in patients with COPD.
Enhanced Reimbursement Incentives for Generic Cancer Drugs Found Not to Affect Prescribing Patterns
Critics of the study say they are not surprised by the study’s conclusions, as oncologists make treatment decisions based on best treatment course, not money.
Cardiorespiratory Fitness Tied to Lower Risk for Lung Cancer, CRC
Higher cardiorespiratory fitness (CRF) is associated with a lower risk for incident lung and colorectal cancer and with a lower risk for all-cause mortality among those diagnosed with lung and colorectal cancer.
A Novel Method for Biomarker Discovery in Clinical Trials
A new study reveals a unique method of biomarker discovery that has the potential to be used to identify responder subpopulations in clinical trials.
Study Reports Marijuana Use Among Patients With Cancer May Be Increasing While Opioid Use Stays Stable, but Questions Remain
The proportion of participants with cancer who used marijuana increased 118% from the period of 2005 to 2014.
Pembrolizumab Improves Survival vs Chemotherapy in NSCLC
Treatment with pembrolizumab may be more effective than chemotherapy for improving overall survival in patients with locally advanced or metastatic non-small-cell lung cancer.
Next post in Lung Cancer
